Zynext Ventures USA, the venture capital arm of Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has invested an undisclosed amount in Canadian early clinical-stage pharmaceutical Feldan Therapeutics, according to a Wednesday filing to the Indian bourses.
Feldan is developing treatments based on intracellular delivery of therapeutics. Its Shuttle peptide technology aids in the targeted delivery of biomolecules into cells.
"We are pleased to support Feldan in exploring a potentially safe and targeted option for patients with dermatological and pulmonary diseases," said Zydus' managing director, Sharvil Patel.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments